Missing Biotin Reveals Cancer Cells' Achilles' Heel

Researchers at the University of Lausanne show that cancer cells' ability to bypass glutamine scarcity relies on biotin-activated pyruvate carboxylase; removing biotin disables this bypass, halting growth, and FBXW7 mutations can intensify this vulnerability, suggesting a multi-pathway therapeutic target and explaining why some glutamine-blocking treatments fail.